Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The UL16-binding protein (ULBP) family, also known as the RAET1 family, comprises six human glycoproteins (ULBP1-6) that function as ligands for the NKG2D activating receptor found on natural killer (NK) cells and various T cell subsets [1][2]. These proteins are structurally homologous to MHC class I molecules but do not present peptides or associate with beta-2 microglobulin [3]. Under normal physiological conditions, ULBPs are minimally expressed on healthy tissues; however, they are rapidly upregulated in response to cellular stressors such as DNA damage, viral infection, or oncogenic transformation [4][5]. This "induced-self" expression marks compromised cells for elimination by the immune system, making the ULBP family a high-priority target for cancer immunotherapies, including CAR-T cells and bispecific engagers [6][7]. Clinical candidates like CYAD-01 utilize the NKG2D receptor to target the broad expression of ULBPs across multiple hematological and solid malignancies [8]. A significant challenge in targeting this family is the proteolytic shedding of ULBPs from the cell surface, which creates soluble decoys that can desensitize NKG2D receptors and facilitate tumor immune evasion [9].
Activation of the NKG2D receptor on natural killer (NK) cells and cytotoxic T cells to induce targeted lysis of cells expressing ULBP ligands.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UL16-binding protein family (ULBP).